Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)

F. Stephen Hodi; Antoni Ribas; Adil Daud; Omid Hamid; Caroline Robert; Richard Kefford; Wen‐Jen Hwu; Tara C. Gangadhar; Anthony M. Joshua; Peter Hersey; Jeffrey S. Weber; Richard W. Joseph; Hassane M. Zarour; Roxana Dronca; Linda Gammage; Darcy A. Hille; Dahai Xue; Soonmo Peter Kang; Patrick Chun; Scot Ebbinghaus; Andrea Perrone; Jedd D. Wolchok

doi:10.1186/2051-1426-2-s3-p103

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Meeting abstracts Unique patterns of response have been observed with immunotherapies. Notably, objective response and prolonged disease stabilization can occur after an initial increase in tumor burden. irRC were developed to better characterize response to immunotherapy based on data for

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hodi et al. (2014) studied this question.

synapsesocial.com/papers/6a12a8bb49a1b84031a41073 https://doi.org/10.1186/2051-1426-2-s3-p103

View Full Paper

Ask AI

Bookmark

Share

Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)

Ask about this paper

Abstract

Discussion

Cite This Study

Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading